Arcus Biosciences Stock Quote RCUS - Stock Price, News, Charts, Message Board, Trades

Professional-Grade Tools, for Individual Investors.

Premium

Current Price

16.43

Bid

Ask

Volume

0.00 Day's Range 0.00

13.495 52 Week Range 20.31

Market Cap

1.504B

Previous Close

16.43

Open

Last Trade

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

700,208

Shares Outstanding

91,511,609

Dividend Yield

PE Ratio

-4.90

Earnings Per Share (EPS)

-3.35

Revenue

117M

Net Profit

-307M

Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule... Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB680, and Zimberelimab. Arcus conducts clinical trials for different types of cancers such as Prostate, Lung, Colorectal, Pancreatic, and others. The company operates through the single segment being the business of developing and commercializing immunotherapies. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.arcusbio.com

Headquarters

Camden, Delaware, USA

Founded

Arcus Biosciences Inc is listed in the Pharmaceutical Preparations sector of the New York Stock Exchange with ticker RCUS. The last closing price for Arcus Biosciences was $16.43. Over the last year, Arcus Biosciences shares have traded in a share price range of $ 13.495 to $ 20.31.

Arcus Biosciences currently has 91,511,609 shares outstanding. The market capitalization of Arcus Biosciences is $1.50 billion. Arcus Biosciences has a price to earnings ratio (PE ratio) of -4.90.

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today...

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Arcus Biosciences Reports Third-Quarter 2024 Financial Results and Provides a Pipeline Update

Data from the Phase 1/1b ARC-20 study of casdatifan were presented at an oral plenary session at the 2024 EORTC-NCI-AACR Symposium; a low rate of primary progression (19%) and promising...

Arcus Biosciences Announces that Domvanalimab Plus Zimberelimab Improved Overall Survival in ARC-10, a Randomized Study in Patients with PD-L1-High Non-Small Cell Lung Cancer

Domvanalimab plus zimberelimab was associated with greater progression-free survival, overall survival, and objective response rate compared with those of zimberelimab or chemotherapy A 36...

Arcus Biosciences to Present New Data for Anti-TIGIT Domvanalimab Plus Zimberelimab at the Society for Immunotherapy of Cancer Annual Meeting

Data, including overall survival, from ARC-10, a randomized study evaluating domvanalimab plus zimberelimab in front-line, PD-L1-high, locally advanced or metastatic non-small cell lung cancer...

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today...

Form 8-K - Current report

First Clinical Data for Arcus Biosciences’ HIF-2a Inhibitor, Casdatifan, Showed Promising Clinical Activity and Tumor Shrinkage in Patients with Metastatic Kidney Cancer

Objective response rate of 34% (2 responses pending confirmation) and 25% (confirmed) in the 100mg daily dose expansion cohort (n=32) of ARC-20, a Phase 1/1b study of casdatifan in metastatic...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.3	1.8598884067	16.13	18.98	15.3	1147121	17.00303907	CS
4	-1.57	-8.72222222222	18	18.98	15	931697	16.83148151	CS
12	-1.28	-7.22755505364	17.71	18.98	14.81	700208	16.83667093	CS
26	-1.07	-6.11428571429	17.5	18.98	13.52	695246	16.2790995	CS
52	2.54	18.286537077	13.89	20.31	13.495	730517	16.62091377	CS
156	-21.78	-57.0007851348	38.21	49.1	12.95	875862	22.5495289	CS
260	8.36	103.593556382	8.07	49.1	7.19	736145	23.89438168	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
IIFMorgan Stanley India Investment Fund Inc	$ 42.50 (55.34%)	1
FETForum Energy Technologies Inc	$ 20.00 (30.80%)	14
ZETAZeta Global Holdings Corp	$ 20.37 (14.70%)	1.14M
TRAKReposiTrak Inc	$ 24.00 (11.94%)	1
QBTSD Wave Quantum Inc	$ 1.99 (11.80%)	695.32k
TWNTaiwan Fund Inc	$ 33.22 (-22.89%)	8
IBTAIbotta Inc	$ 58.99 (-21.27%)	1.79k
CSRCenterspace	$ 61.10 (-17.33%)	203
CVLGCovenant Logistics Group Inc	$ 51.00 (-15.53%)	101
GWHESS Tech Inc	$ 7.68 (-13.71%)	5k
IONQIonQ Inc	$ 27.60 (3.14%)	1.26M
ZETAZeta Global Holdings Corp	$ 20.37 (14.70%)	1.14M
QBTSD Wave Quantum Inc	$ 1.99 (11.80%)	695.32k
NIONIO Inc	$ 4.51 (-2.17%)	430.55k
PLTRPalantir Technologies Inc	$ 61.79 (1.80%)	408.4k